Zentalis Q2 2022 Earnings Report
Key Takeaways
Zentalis Pharmaceuticals reported its Q2 2022 financial results, highlighting the strengthening of its leadership team, a $25 million equity investment from Pfizer, and approximately $200.2 million in gross proceeds from a recent follow-on offering, extending the company's cash runway into 2025. The company is focusing on advancing its lead clinical candidates, ZN-c3 and ZN-d5, while discontinuing the development of ZN-c5 and ZN-e4.
Received a $25 million equity investment from Pfizer to jointly advance and expand clinical development of ZN-c3.
Raised approximately $200.2 million in gross proceeds from a recent follow-on offering, extending cash runway into 2025.
Appointed Kimberly Blackwell, M.D. as Chief Executive Officer.
Focusing resources on investigating the full potential of ZN-c3 and ZN-d5, and discontinuing the clinical development of ZN-c5 and ZN-e4.